In this work, we tested the hypothesis that Janus kinase 1/2 (JAK1/2) inhibition with ruxolitinib might prevent and attenuate CTEPH in a rat model. The gene discussed is JAK1; the disease is chronic thromboembolic pulmonary hypertension.